Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)
Diabetes News
Category: Hepatology
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial
Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population (JCEM)
Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study
Our findings demonstrate that prediabetic patients show a lower phenotypic flexibility after external aggression, such as OFTT compared with nondiabetic patients. The postprandial response increases progressively according to non-diabetic, prediabetic and type 2 diabetic state and it is higher in patients with liver insulin-resistance. To identify this subgroup of patients is important to treat more intensively in order to avoid future cardiometabolic complications (Cardiovascular Diabetology)
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
Fatty Liver Index assessed nonalcoholic fatty liver disease (FLI-NAFLD) was present in the majority of T2DM patients of our sample and metabolic derangement, not alcohol consumption, was mainly associated with the disease. FLI-NAFLD patients have a worse metabolic profile (Journal of Diabetes Research)
Assessment of the relation between non-alcoholic fatty liver disease and diabetic complications
NAFLD combined with type 2 diabetes is associated with the presence of significant coronary artery disease and hypertension (Journal of Diabetes Investigation)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)
Effect of T2D on risk of hepatocellular carcinoma in chronic Hep C
T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN (Hepatology)
Glycosmedia is also available as an App: